StreetInsider.com News Articles

WuXi Biologics Recognized by FTSE4Good for the Sixth Consecutive Year, Underscoring Value Creation Through Green CRDMO

Tue, 28 Jul 2026 22:27:00 -0400

SHANGHAI, July 28, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced that it has been included in the FTSE4Good Index Series in recognition of its outstanding sustainability performance, marking the sixth consecutive year the company has received this distinction. The inclusion further underscores WuXi Biologics' long-term leadership in Environmental, Social and Governance (ESG) and highlights the Company's ability to consistently create value for global partners through its Green CRDMO solutions.

The FTSE4Good Index Series, launched in 2001 by

WuXi Biologics Recognized by FTSE4Good for the Sixth Consecutive Year, Underscoring Value Creation Through Green CRDMO

Tue, 28 Jul 2026 22:27:00 -0400

The FTSE4Good Index Series, launched in 2001 by

WuXi Biologics Recognized by FTSE4Good for the Sixth Consecutive Year, Underscoring Value Creation Through Green CRDMO

Tue, 28 Jul 2026 22:27:00 -0400

The FTSE4Good Index Series, launched in 2001 by

WuXi Biologics Recognized by FTSE4Good for the Sixth Consecutive Year, Underscoring Value Creation Through Green CRDMO

Tue, 28 Jul 2026 22:27:00 -0400

The FTSE4Good Index Series, launched in 2001 by

WuXi Biologics Recognized by FTSE4Good for the Sixth Consecutive Year, Underscoring Value Creation Through Green CRDMO

Tue, 28 Jul 2026 22:27:00 -0400

The FTSE4Good Index Series, launched in 2001 by

WuXi Biologics Recognized by FTSE4Good for the Sixth Consecutive Year, Underscoring Value Creation Through Green CRDMO

Tue, 28 Jul 2026 22:27:00 -0400

The FTSE4Good Index Series, launched in 2001 by

WuXi Biologics Recognized by FTSE4Good for the Sixth Consecutive Year, Underscoring Value Creation Through Green CRDMO

Tue, 28 Jul 2026 22:27:00 -0400

The FTSE4Good Index Series, launched in 2001 by

WuXi Biologics Recognized by FTSE4Good for the Sixth Consecutive Year, Underscoring Value Creation Through Green CRDMO

Tue, 28 Jul 2026 22:27:00 -0400

The FTSE4Good Index Series, launched in 2001 by

WuXi Biologics Recognized by FTSE4Good for the Sixth Consecutive Year, Underscoring Value Creation Through Green CRDMO

Tue, 28 Jul 2026 22:27:00 -0400

The FTSE4Good Index Series, launched in 2001 by

WuXi Biologics Recognized by FTSE4Good for the Sixth Consecutive Year, Underscoring Value Creation Through Green CRDMO

Tue, 28 Jul 2026 22:27:00 -0400

The FTSE4Good Index Series, launched in 2001 by

Wuxi Biologics (2269:HK) (WXXWY) PT Raised to HK$51.38 at Nomura/Instinet

Mon, 27 Jul 2026 07:43:47 -0400

Nomura/Instinet analyst Jialin Zhang raised the price target on Wuxi Biologics (2269:HK) (OTC: WXXWY) to HK$51.38 (from HK$50.54) while maintaining a Buy rating.

Wuxi Biologics (2269:HK) (WXXWY) PT Raised to HK$51.38 at Nomura/Instinet

Mon, 27 Jul 2026 07:43:47 -0400

Nomura/Instinet analyst Jialin Zhang raised the price target on Wuxi Biologics (2269:HK) (OTC: WXXWY) to HK$51.38 (from HK$50.54) while maintaining a Buy rating.

Wuxi Biologics (2269:HK) (WXXWY) PT Raised to HK$51.38 at Nomura/Instinet

Mon, 27 Jul 2026 07:43:47 -0400

Nomura/Instinet analyst Jialin Zhang raised the price target on Wuxi Biologics (2269:HK) (OTC: WXXWY) to HK$51.38 (from HK$50.54) while maintaining a Buy rating.

Wuxi Biologics (2269:HK) (WXXWY) PT Raised to HK$51.38 at Nomura/Instinet

Mon, 27 Jul 2026 07:43:47 -0400

Nomura/Instinet analyst Jialin Zhang raised the price target on Wuxi Biologics (2269:HK) (OTC: WXXWY) to HK$51.38 (from HK$50.54) while maintaining a Buy rating.

Bernstein SocGen Group Starts Wuxi Biologics (2269:HK) (WXXWY) at Market Perform

Tue, 14 Jul 2026 06:31:57 -0400

Bernstein SocGen Group analyst Rebecca Liang initiates coverage on Wuxi Biologics (2269:HK) (OTC: WXXWY) with a Market Perform rating and a price target of HK$42.00.

The analyst comments: “WuXi Biologics remains the leading biologics CRDMO platform in China and has built one of the industry's largest global biologics manufacturing networks. The company has been a key beneficiary of growing demand for biologics, ADCs and bispecific antibodies, and we forecast revenue growth from CNY22bn in 2025 to CNY45bn by 2030E. However, unlike WuXi AppTec in small molecules, we do not believe WuXi Biologics has yet established comparable leadership in late-stage and commercial

Bernstein SocGen Group Starts Wuxi Biologics (2269:HK) (WXXWY) at Market Perform

Tue, 14 Jul 2026 06:31:57 -0400

Bernstein SocGen Group analyst Rebecca Liang initiates coverage on Wuxi Biologics (2269:HK) (OTC: WXXWY) with a Market Perform rating and a price target of HK$42.00.

Bernstein SocGen Group Starts Wuxi Biologics (2269:HK) (WXXWY) at Market Perform

Tue, 14 Jul 2026 06:31:57 -0400

Bernstein SocGen Group analyst Rebecca Liang initiates coverage on Wuxi Biologics (2269:HK) (OTC: WXXWY) with a Market Perform rating and a price target of HK$42.00.

Bernstein SocGen Group Starts Wuxi Biologics (2269:HK) (WXXWY) at Market Perform

Tue, 14 Jul 2026 06:31:57 -0400

Bernstein SocGen Group analyst Rebecca Liang initiates coverage on Wuxi Biologics (2269:HK) (OTC: WXXWY) with a Market Perform rating and a price target of HK$42.00.

Bernstein SocGen Group Starts Wuxi Biologics (2269:HK) (WXXWY) at Market Perform

Tue, 14 Jul 2026 06:31:57 -0400

Bernstein SocGen Group analyst Rebecca Liang initiates coverage on Wuxi Biologics (2269:HK) (OTC: WXXWY) with a Market Perform rating and a price target of HK$42.00.

Bernstein SocGen Group Starts Wuxi Biologics (2269:HK) (WXXWY) at Market Perform

Tue, 14 Jul 2026 06:31:57 -0400

Bernstein SocGen Group analyst Rebecca Liang initiates coverage on Wuxi Biologics (2269:HK) (OTC: WXXWY) with a Market Perform rating and a price target of HK$42.00.

Wuxi Biologics (2269:HK) (WXXWY) PT Raised to HK$51.90 at CLSA

Mon, 13 Jul 2026 07:58:25 -0400

CLSA analyst Michael Luo raised the price target on Wuxi Biologics (2269:HK) (OTC: WXXWY) to HK$51.90 (from HK$46.60) while maintaining a Outperform (2) rating.

Wuxi Biologics (2269:HK) (WXXWY) PT Raised to HK$51.90 at CLSA

Mon, 13 Jul 2026 07:58:25 -0400

CLSA analyst Michael Luo raised the price target on Wuxi Biologics (2269:HK) (OTC: WXXWY) to HK$51.90 (from HK$46.60) while maintaining a Outperform (2) rating.

Wuxi Biologics (2269:HK) (WXXWY) PT Raised to HK$51.90 at CLSA

Mon, 13 Jul 2026 07:58:25 -0400

CLSA analyst Michael Luo raised the price target on Wuxi Biologics (2269:HK) (OTC: WXXWY) to HK$51.90 (from HK$46.60) while maintaining a Outperform (2) rating.

Wuxi Biologics (2269:HK) (WXXWY) PT Raised to HK$51.90 at CLSA

Mon, 13 Jul 2026 07:58:25 -0400

CLSA analyst Michael Luo raised the price target on Wuxi Biologics (2269:HK) (OTC: WXXWY) to HK$51.90 (from HK$46.60) while maintaining a Outperform (2) rating.

WuXi Biologics' MFG8 Drug Substance Facility Secures FDA PLI Approval, Advancing Commercial Supply of a Potential Blockbuster Autoimmune Therapy

Thu, 09 Jul 2026 03:31:00 -0400

SHIJIAZHUANG, China, July 9, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that its MFG8 drug substance manufacturing facility located in Hebei has successfully passed the Pre-License Inspection (PLI) by the U.S. Food and Drug Administration (FDA), supporting commercial manufacturing for a potential blockbuster autoimmune therapy.

The seven-day FDA inspection conducted by three inspectors covered MFG8's quality management system and drug substance manufacturing processes. Passing this inspection further reinforces WuXi Biologics' outstanding regulatory compliance track record and demonstrates